Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3355 |
|
| Actual shortage: | 217 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
61 (25%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO PREDNISONE TAB 5MG | 5MG | TABLET | Resolved | 2020-05-08 | 2020-06-02 | 114315 |
| APO-PROPRANOLOL | 10MG | TABLET | Actual shortage | 2017-08-11 | 2017-10-05 | 18913 |
| APO-PROPRANOLOL | 120MG | TABLET | Actual shortage | 2017-08-13 | 2017-10-05 | 18951 |
| APO-PROPRANOLOL | 40MG | TABLET | Resolved | 2017-08-11 | 2020-02-13 | 18769 |
| APO-PROPRANOLOL | 80MG | TABLET | Actual shortage | 2017-08-11 | 2017-10-05 | 18910 |
| APO TRIAZIDE | 50MG 25MG | TABLET | Resolved | 2017-11-01 | 2018-02-17 | 27770 |
| APO TRIAZIDE | 50MG 25MG | TABLET | Resolved | 2021-03-05 | 2021-06-14 | 135181 |
| APO TRIAZIDE | 50MG 25MG | TABLET | Resolved | 2017-05-16 | 2017-07-20 | 10439 |
| APO TRIAZIDE | 25MG 50MG | TABLET | Resolved | 2023-11-06 | 2023-11-10 | 209357 |
| APO TRIAZIDE | 25MG 50MG | TABLET | Resolved | 2024-03-08 | 2024-04-05 | 221702 |
| APO TRIAZIDE | 50MG 25MG | TABLET | Resolved | 2020-11-04 | 2020-12-31 | 127762 |
| APO-ABACAVIR | 300MG | TABLET | Resolved | 2017-03-10 | 2017-04-28 | 8 |
| APO-ABACAVIR | 300MG | TABLET | Resolved | 2024-08-29 | 2024-09-27 | 236249 |
| APO-ABACAVIR | 300MG | TABLET | Resolved | 2018-01-03 | 2018-01-18 | 34826 |
| APO-ABACAVIR | 300MG | TABLET | Resolved | 2018-11-16 | 2019-01-23 | 67019 |
| APO-ABACAVIR | 300MG | TABLET | Resolved | 2022-04-06 | 2022-08-11 | 157992 |
| APO-ABACAVIR | 300MG | TABLET | Resolved | 2023-07-13 | 2023-08-12 | 198465 |
| APO-ABACAVIR-LAMIVUDINE | 600MG 300MG | TABLET | Resolved | 2019-04-22 | 2019-07-29 | 82102 |
| APO-ABACAVIR-LAMIVUDINE | 600MG 300MG | TABLET | Resolved | 2019-08-21 | 2020-01-27 | 92016 |
| APO-ABACAVIR-LAMIVUDINE | 600MG 300MG | TABLET | Resolved | 2019-01-03 | 2019-01-23 | 71098 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-LAMIVUDINE | 300MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60560 |
| APO-LAMIVUDINE HBV | 100MG | TABLET | Discontinued | 2018-09-07 | 2019-12-21 | 60563 |
| APO-LATANOPROST-TIMOP | Discontinued | 2018-09-07 | 2018-09-15 | 60572 | ||
| APO-LEVOCARB | 25MG 250MG | TABLET | Discontinued | 2018-09-07 | 2019-02-07 | 60576 |
| APO-LISINOPRIL | 10MG | TABLET | Discontinued | 2018-09-07 | 2019-02-02 | 60579 |
| APO-LISINOPRIL | 20MG | TABLET | Discontinued | 2018-09-07 | 2018-11-26 | 60582 |
| APO-LISINOPRIL | 5MG | TABLET | Discontinued | 2018-09-07 | 2019-02-13 | 60585 |
| APO-LISINOPRIL/HCTZ | 12.5MG 20MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1090 |
| APO-LISINOPRIL/HCTZ | 12.5MG 10MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1093 |
| APO-LISINOPRIL/HCTZ | 25MG 20MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1096 |
| APO-LITHIUM CARBONATE | 300MG | CAPSULE | Discontinued | 2018-09-07 | 2018-09-15 | 60588 |
| APO-LOPERAMIDE | 2MG | TABLET | Discontinued | 2017-03-31 | 2017-03-31 | 4930 |
| APO-LORAZEPAM | 0.5MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60591 |
| APO-LORAZEPAM | 1MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60594 |
| APO-LOSARTAN | 25MG | TABLET | Discontinued | 2019-02-01 | 2019-02-02 | 74376 |
| APO-LOSARTAN | 50MG | TABLET | Discontinued | 2018-09-10 | 2018-09-15 | 60987 |
| APO-LOSARTAN | 100MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71213 |
| APO-LOSARTAN/HCTZ | 12.5MG 100MG | TABLET | Discontinued | 2018-09-07 | 2018-11-02 | 60597 |
| APO-LOSARTAN/HCTZ | 25MG 100MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60600 |
| APO-LOSARTAN/HCTZ | 12.5MG 50MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60603 |